Amgen (NASDAQ:AMGN) said on Monday that it has launched its cholesterol medication, Repatha, directly to consumers in the U.S ...
In alignment with the Trump administration’s efforts to lower drug prices, Amgen today launched AmgenNow, a direct-to-patient program offering evolocumab (Repatha) at a monthly price of $239, nearly ...
Amgen will offer its lipid-lowering drug Repatha directly to patients for $239 per month, representing a nearly 60% reduction ...
Amgen launches AmgenNow, offering Repatha at $239 per month, expanding direct access for U.S. patients with no insurer ...
Clinical Trials Arena on MSN
Long-term benefit of Amgen’s Repatha in reducing MACE shown in Phase III trial
Amgen's Repatha (evolocumab) has shown benefit in a long-term study in reducing cardiovascular incidents in patients without ...
Amgen introduces AmgenNow, a direct-to-patient program for Repatha, offering affordable access to life-saving cardiovascular ...
Amgen launched a direct-to-patient program Oct. 6 to offer its cholesterol medication Repatha at a reduced price. The AmgenNow program will ...
GoodRx, an online platform that offers drug discount coupons to patients, is in talks with the government to participate in ...
Amgen makes Repatha available through AmgenNow, a direct-to-patient programme in the US: Thousand Oaks, California Wednesday, October 8, 2025, 17:00 Hrs [IST] Amgen announced the ...
Amgen on Monday launched direct-to-consumer U.S. sales of its cholesterol-lowering medication Repatha at a discounted cash ...
US biotech major Amgen is the latest drugmaker to announce direct-to-consumer access of medicines, adding to the first such ...
In today's Pharmalittle roundup, we're reading about Novo Nordisk layoffs, an Amgen discount program, and more.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback